Sign Out
Recommended Dose: Pegfilgrastim therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
Adults: One 6 mg dose (a single pre-filled syringe) of pegfilgrastim is recommended for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Special populations: Paediatric use: The safety and efficiency of pegfilgrastim in children and adolescents under 18 years of age have not been established.
Renal impairment: No dosage adjustment is required for patients with in renal impairment.
Hepatic impairment: No dosage adjustment is required for patients with in hepatic impairment.
Mode of Administration: Pegfilgrastim is injected subcutaneously via the thigh, abdomen or upper arm.
